Stable pharmaceutical composition and methods of using same
View Patent ↗The present invention relates to, inter alia, pharmaceutical compositions comprising a polyunsaturated fatty acid and to methods of using the same to treat or prevent cardiovascular-related diseases.
1. A method of lowering triglycerides in a subject with triglycerides of at least 500 mg/dl comprising, administering to the subject daily for a period effective to reduce triglycerides in the subject a pharmaceutical composition comprising omega-3 fatty acids including: (a) about 1100 mg to about 1200 mg of eicosapentaenoic acid; (b) docosahexaenoic acid, and (c) docosapentaenoic acid, wherein the docosahexaenoic acid comprises not more than about 20% by weight of fatty acids in the composition, and the docosapentaenoic acid comprises not more than about 7% by weight of fatty acids present in the composition.
2. The method of claim 1 wherein the composition is present in one or more dosage units.
3. The method of claim 2 wherein the dosage units comprise capsules.
4. A method of lowering triglycerides in a subject with triglycerides of at least 500 mg/dl comprising, administering to the subject daily for a period effective to reduce triglycerides in the subject a pharmaceutical composition comprising omega-3 fatty acids including: (a) about 1700 mg to about 1800 mg of eicosapentaenoic acid; (b) docosahexaenoic acid, and (c) docosapentaenoic acid, wherein the docosahexaenoic acid comprises not more than about 20% by weight of fatty acids in the composition, and the docosapentaenoic acid comprises not more than about 7% by weight of fatty acids in the composition.
5. The method of claim 4 wherein the composition is present in one or more dosage units.
6. The method of claim 5 wherein the one or more dosage units comprise capsules.
7. A method of lowering triglycerides in a subject with triglycerides of at least 500 mg/dl comprising, administering to the subject daily for a period effective to reduce triglycerides in the subject a pharmaceutical composition comprising omega-3 fatty acids including: (a) about 2200 mg to about 2300 mg of eicosapentaenoic acid; (b) docosahexaenoic acid, and (c) docosapentaenoic acid, wherein the docosahexaenoic acid comprises not more than about 20% by weight of fatty acids in the composition, and the docosapentaenoic acid comprises not more than about 7% by weight of fatty acids in the composition.
8. The method of claim 7 wherein the composition is present in one or more dosage units.
9. The method of claim 8 wherein the one or more dosage units comprise capsules.